Tested Applications
| Positive WB detected in | 4T1 cells, MCF-7 cells, MDA-MB-453 cells, SGC-7901 cells, HeLa cells |
| Positive IP detected in | SGC-7901 cells |
| Positive IHC detected in | human breast cancer tissue, human ovary cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-Fro detected in | mouse breast cancer |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:12000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:300-1:1200 |
| Immunofluorescence (IF)-FRO | IF-FRO : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
18299-1-AP targets HER2/ErbB2 in WB, IHC, IF-Fro, IP, CoIP, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat, zebrafish |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
| Calculated Molecular Weight | 138 kDa |
| Observed Molecular Weight | 185 kDa |
| GenBank Accession Number | BC167147 |
| Gene Symbol | HER2/ErbB2 |
| Gene ID (NCBI) | 2064 |
| RRID | AB_2099264 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P04626 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
| IHC protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
| IP protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
| WB protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The HER2/ErbB2 Polyclonal antibody (catalog no. 18299-1-AP) has 112 citations. These appear across journals including Nature Communications, Cell Metabolism, Cell Research, Cancer Research, Molecular Cell, Advanced Science, Cell Reports, Journal of Biological Chemistry, ACS Nano, Small, Oncotarget, and Scientific Reports, among others. Research fields are dominated by oncology—breast, lung, gastric, ovarian, bladder, prostate, colorectal, and pancreatic cancers—focusing on ERBB2/PI3K/AKT/mTOR signaling, drug resistance, ferroptosis, immunotherapy, and HER2-targeted diagnostics. Applications include WB, IHC, IF, IP, and ELISA.
| Species | Application | Title |
|---|---|---|
Signal Transduct Target Ther Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis | ||
Cell Metab Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity | ||
Cell Res Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. | ||
Cancer Res Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. | ||
Nat Commun Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. | ||
Nat Commun TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression |
Reviews
What customers say
The single review reports successful use of this HER2/Erbb2 antibody in Western blot. The user transfected MDA-MB-453 breast cancer cells with HER2/Erbb2 siRNA at varying concentrations for 48 hours, then confirmed effective knockdown using the antibody at a 1:2,000 dilution. The reviewer rated the product 5 stars, indicating satisfaction with its performance in detecting the expected reduction in HER2/Erbb2 protein levels.
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
Vanina (Verified Customer) (07-28-2021) | MDA-MB-453 cell line was transfected with different concentrations of HER2/Erbb2 siRNA for 48h. Western blot using HER2/Erbb2 rabbit Proteintech antibody (18299-1-AP) at 1:2,000 dillution confirms the HER2/Erbb2 knockdown.
 |
